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Abstract African men who have sex with men (MSM)
face significant stigma and barriers to care. We investi-
gated antiretroviral therapy (ART) adherence among high-
risk adults, including MSM, participating in a clinic-based
cohort. Survival analysis was used to compare attrition
across patient groups. Differences in adherence, weight
gain, and CD4 counts after ART initiation were assessed.
Among 250 HIV-1-seropositive adults, including 108
MSM, 15 heterosexual men, and 127 women, patient group
was not associated with attrition. Among 58 participants
who were followed on ART, 40 % of MSM had less than
95 % adherence, versus 28.6 % of heterosexual men and
11.5 % of women. Although MSM gained less weight after
ART initiation than women (adjusted difference -3.5 kg/
year), CD4 counts did not differ. More data are needed on
barriers to adherence and clinical outcomes among African
MSM, to ensure that MSM can access care and derive
treatment and prevention benefits from ART.
Resumen En A´frica los hombres que tienen sexo con
hombres (HSH) sufren un nivel importante de estigma y
encuentran obsta´culos a la atencio´n me´dica. Investigamos
la adhesio´n al tratamiento antirretroviral (TAR) en un
grupo de adultos de alto riesgo (el cual incluyo´ HSH) que
participo´ en una cohorte de una clı´nica. Utilizamos el an-
a´lisis de supervivencia para comparar el abandono de
participantes en los distintos grupos. Evaluamos las difer-
encias en la adhesio´n al TAR, aumento de peso, y los
recuentos de CD4 desde el inicio de TAR. En los 250
adultos con VIH-1, que incluyeron 108 HSH, 15 hombres
heterosexuales y 127 mujeres, no observa´ndose abandono.
De los 58 participantes que tuvieron seguimiento mientras
recibı´an TAR, el 40 % de los HSH tuvo \95 % de adhe-
sio´n, versus el 28.6 % de los hombres heterosexuales y el
11.5 % de las mujeres. Aunque los HSH subieron menos
peso que las mujeres despue´s del inicio del TAR (difer-
encia ajustada -3.5 kg/an˜o), el recuento de CD4 no fue
diferente. Concluimos que es necesario profundizar la in-
vestigacio´n sobre las asociaciones entre las barreras a la
adhesio´n al TAR y los resultados clı´nicos en los HSH de
A´frica, para garantizar que ellos tengan acceso a la ate-
ncio´n me´dica y ası´ beneficiarse del tratamiento y de la
prevencio´n que provee el TAR.
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Introduction
Sub-Saharan Africa has a very high burden of HIV-1
infection, of which a substantial proportion (estimated at
29 % in Kenya) occurs among populations reporting high-
risk sexual behavior such as transactional sex and anal
intercourse [1]. Such populations suffer from stigma and
discrimination, and have been neglected by many HIV
prevention and care programs [1]. In particular, men who
have sex with men (MSM) have only recently become a
focus for HIV programs in this region [1–4].
Because MSM are highly stigmatized by prevailing
attitudes and laws against adult same-sex behavior in most
African countries [5], they may be reluctant to access care
and lack trust in providers [6, 7]. Access to antiretroviral
therapy (ART), retention in care, and adherence to treat-
ment are critical determinants of health outcomes among
HIV-1-infected individuals [8–12]. In addition, ART pre-
vents transmission to the sexual partners of treated indi-
viduals [13, 14], and high uptake could significantly
decrease new infections among MSM and on a population
level [13, 15]. However, little is known about antiretroviral
adherence among this group.
We and others have identified MSM as an important
HIV risk group on the Kenyan coast [16–18]. Since 2004,
we have conducted HIV prevention research and offered
ART to eligible HIV-1-infected individuals from high-risk
groups including MSM, female sex workers (FSW), and
persons with multiple sexual partners. We describe here
our experience in providing ART to this population. We
hypothesized that Kenyan MSM would have delayed
engagement in care, lower ART adherence, and worse
clinical outcomes compared to high-risk men and women
participating in the same HIV-1-seropositive cohort.
Methods
Study Population
The study population consisted of participants in a pro-
spective cohort based in a research clinic north of Mom-
basa, Kenya. Adults aged 18–49 years were eligible if they
resided in the clinic catchment area (i.e., the coastal region
from Kilifi in the north to Mombasa in the south), were
HIV-1-seropositive, and reported transactional sex work,
multiple sexual partners, anal sex, or a recent sexually
transmitted infection (STI). HIV-1-seronegative persons
enrolled in a parallel clinic-based cohort that has been
described previously [17]. Identification and recruitment of
potential study participants was carried out by trained peer
mobilizers, who approached individuals via personal net-
works and at venues where high-risk sex was common.
Clinical Procedures
Eligibility screening and cohort enrollment were carried
out by trained research staff with experience in HIV
counseling and testing. These staff conducted all research
visits for participants in the two cohorts (i.e., HIV-sero-
positive and HIV-seronegative) according to established
protocols. At enrollment, participants completed face-to-
face or audio computer-assisted interviews using stan-
dardized questionnaires to record recent sexual behavior
and health status. A standardized physical exam was per-
formed, and specimens were collected for STI screening.
Participants with genital symptoms were provided syn-
dromic treatment, and laboratory-diagnosed infections
were treated following Kenyan Ministry of Health guide-
lines. Risk reduction counseling, condoms, and lubricants
were provided. These procedures were repeated at quar-
terly follow-up visits.
At enrolment and each subsequent visit, participants
were reviewed for ART eligibility according to Kenyan
National Guidelines during this period (CD4 count B250
cells/lL or AIDS-defining illness). All eligible participants
were offered ART at the time of eligibility. Data on ART
status were recorded at each visit. Neither ART eligibility
nor uptake was required for cohort participation, and cohort
participants were free to initiate or continue ART at other
local clinics if they preferred. All clinic attendees were
cohort participants, and cohort withdrawal resulted in
transfer of care to another clinic.
The standard ART regimen consisted of stavudine,
zidovudine, or tenofovir with lamivudine and either nevi-
rapine (for women) or efavirenz (for men), according to
Kenyan National Guidelines. Monthly support groups were
used to promote adherence, which was monitored at each
refill by a visual analog scale (VAS) [19]. Refill dates and
the quantity of drug dispensed were also recorded. Partic-
ipants taking ART through the research clinic were tracked
via telephone or in person after any missed visit or refill;
cohort participants not taking ART were not routinely
tracked.
Ethical Approval
The study was approved by ethical review boards at the
Kenya Medical Research Institute and University of
Washington. All participants provided written informed
consent.
Laboratory Testing
HIV-1 status was confirmed using two rapid test kits in
parallel (Determine, Abbott Laboratories, Abbott Park,
Illinois, USA; Unigold, Trinity Biotech, Bray, Ireland).
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Sex of sexual partners reported at enrollment
Opposite sex 140 (56.0) 3 (2.8) 15 (100) 122 (96.1) FE \0.001
Both men and women 45 (18.0) 41 (38.0) 0 4 (3.1)
Same sex 65 (26.0) 64 (59.3) 0 1 (0.8)
Age group
18–24 years 52 (20.8) 26 (24.1) 1 (6.7) 25 (19.7) FE 0.28
25–34 years 143 (57.2) 64 (59.3) 10 (66.7) 69 (54.3)
35 and older 55 (22.0) 18 (16.7) 4 (26.7) 33 (26.0)
Marital status
Single 164 (65.6) 89 (82.4) 7 (46.7) 68 (53.5) FE \0.001
Married 28 (11.2) 11 (10.2) 8 (53.3) 9 (7.1)
Widowed, separated, or divorced 58 (23.2) 8 (7.4) 0 50 (39.4)
Has dependents 136 (54.4) 31 (28.7) 12 (80.0) 93 (73.2) FE \0.001
Educational achievement
None or primary school only 147 (58.8) 63 (58.3) 10 (66.7) 74 (58.3) FE 0.53
Secondary school 85 (34.0) 36 (33.3) 3 (20.0) 46 (36.2)
Higher education 18 (7.2) 9 (8.3) 2 (13.3) 7 (5.5)
Monthly earningsb
C10,000 KSh 38 (15.2) 11 (10.2) 3 (20.0) 24 (18.9) FE 0.015
5,000–9,999 KSh 63 (25.2) 30 (27.8) 8 (53.3) 25 (19.7)
2,000–5,000 KSh 93 (37.2) 38 (35.2) 4 (26.7) 51 (40.2)
\2,000 KSh 56 (22.4) 29 (26.8) 0 27 (21.3)
Transactional sex 187 (74.8) 76 (70.4) 3 (20.0) 108 (85.0) FE \0.001
Alcohol use 166 (66.4) 67 (62.0) 9 (60.0) 90 (70.9) 2.33 0.31
CD4 count
\200 34 (13.6) 17 (15.7) 1 (6.7) 16 (12.6) FE 0.38
200–350 63 (25.2) 24 (22.2) 7 (46.7) 32 (25.2)
[350 153 (61.2) 67 (62.0) 7 (46.7) 79 (62.2)
WHO stagec
I asymptomatic/lymphadenopathy 100 (40.5) 50 (46.7) 6 (40.0) 44 (35.2) FE 0.14
II mild local manifestations 91 (36.8) 41 (38.3) 4 (26.7) 46 (36.8)
III systemic manifestations 54 (21.9) 15 (14.0) 5 (33.3) 34 (27.2)
IV AIDS-defining illness 2 (0.8) 1 (0.9) 0 1 (0.8)
Nutritional status
Severe malnutrition 3 (1.2) 2 (1.8) 0 1 (0.8) FE 0.71
Mild to moderate malnutrition 47 (18.8) 23 (21.3) 3 (20.0) 21 (16.5)
Adequate nutrition 200 (80.0) 83 (76.8) 12 (80.0) 105 (82.7)
Too sick to work, past 3 months
No 209 (83.6) 92 (85.2) 12 (80.0) 105 (82.7) FE 0.76
Yes 41 (16.4) 16 (14.8) 3 (20.0) 22 (17.3)
Prior TBc
No 194 (79.8) 86 (82.7) 12 (80.0) 96 (77.4) FE 0.60
Yes 49 (20.2) 18 (17.3) 3 (20.0) 28 (22.6)
Disclosure of HIV statusc,d
No 141 (56.8) 73 (67.6) 8 (57.1) 60 (47.6) 9.46 0.009
Yes 107 (43.2) 35 (32.4) 6 (42.9) 66 (52.4)
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Discrepant rapid HIV-1 test results were resolved using an
ELISA (Genetic System HIV-1/2 plus O EIA, Bio-Rad
Laboratories, Redmond, Washington, USA). CD4 counts
(FACS Count, Becton–Dickinson) were determined every
3 months if the last count was \350 cells/lL and every
6 months if C350 cells/lL. Plasma viral loads were not
available.
Definitions
Men who have sex with men were defined as men who
reported sex with another man either at enrollment or
subsequently during follow-up. Heterosexual men were
men who never reported a male sexual partner during
cohort participation. Nutritional status was categorized
using the calculated body mass index (BMI) as adequate
(BMI C 18.5), mild or moderate malnutrition (BMI
16–18.49), or severe malnutrition (BMI \ 16) [20]. CD4
counts were categorized as \200 cells/lL, 200–350 cells/
lL, and [350 cells/lL following WHO guidelines for
ART initiation (i.e., \200 prior to 2010, B350 currently)
[21]. Loss to follow-up (from cohort and clinic) was
defined as a final visit C12 months before March 1, 2011,
with no formal notice of withdrawal. Cohort withdrawal
was defined as having formally transferred care elsewhere.
Adherence measures were calculated using primary data
from clinic visits (i.e., VAS result, refill dates, pills dis-
pensed). VAS adherence was 100 % minus the percentage
of pills reported missed over the last 30 days [19].
Adherence by pharmacy records was calculated as the
percentage of days since the last refill on which a pill
supply was available. Overall adherence was the lower of
these two measures. A late or missed refill was defined as
any refill provided after the due date, which was scheduled
for the day on which the pill supply would be exhausted,
assuming no missed doses. Loss to follow-up from the
clinic’s ART program was defined as having missed C3
consecutive monthly refills before the study end date.
Statistical Analysis
Pearson’s v2 or Fisher’s exact (FE) tests were used to
compare categorical predictors across patient groups at
baseline and ART initiation. The Kruskal–Wallis (KW)
equality-of-populations rank test was used to compare non-
normally distributed data (e.g., follow-up time) across
groups. Kaplan–Meier curves were used to characterize
trends in loss to follow-up and in mortality over time
stratified by group, and log-rank tests were used to test for
differences in these curves. Cox regression analysis was
used to evaluate the association between patient group and
loss to follow-up, after adjustment for potential con-
founding factors. For this analysis, data were censored at
the first of cohort withdrawal, death, or March 1, 2011.
ART status was categorized as not taking ART, taking
ART prescribed by the research clinic, or taking ART
prescribed by an outside clinic. Potential confounding
factors included characteristics recorded at enrolment (e.g.,
marital status) and time-dependent covariates updated at

















No 193 (80.1) 89 (84.8) 14 (93.3) 90 (74.4) FE 0.07
Yes 48 (19.9) 16 (15.2) 1 (6.7) 31 (25.6)
Prior ART counselingc
No 204 (83.6) 96 (89.7) 14 (93.3) 94 (77.0) FE 0.02
Yes 40 (16.4) 11 (10.3) 1 (6.7) 28 (23.0)
Prior ART usec
No 208 (88.5) 96 (93.2) 15 (100) 97 (82.9) FE 0.02
Yese 27 (11.5) 7 (6.8) 0 20 (17.1)
FE Fisher’s exact test significance value
a Participants were classified as MSM or heterosexual men based on behavior reported at enrolment or during follow-up
b 1,000 KSh is approximately $11.90
c Data were missing for WHO stage (1 MSM, 2 women), prior TB (4 MSM, 3 women), disclosure (1 heterosexual man, 1 woman), cotrim-
oxazole use (3 MSM, 6 women), prior ART counseling (1 MSM, 5 women), and prior ART use (5 MSM, 10 women)
d Disclosure was defined as informing anyone other than the counselor or medical staff (e.g., family, partner, friend, other) about one’s HIV
infection
e Includes 5 women who had taken ART for PMTCT
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(i.e., group, age category) and those with a p value \0.10
in bivariable analysis were selected for inclusion in mul-
tivariable models.
For an analysis of outcomes after ART initiation, only
participants who started ART in the research clinic and had
at least one on-treatment follow-up visit were included.
Log-rank tests were used to test for differences in the
hazard functions for loss to follow-up and mortality. Data
from all visits after ART initiation were aggregated to
calculate mean adherence and any late refills or adherence
\95 %. These data were compared across patient groups,
using KW equality-of-populations rank tests, Pearson’s v2,
or FE tests, as appropriate. Data from the first 12 months
after ART initiation were analyzed to evaluate clinical
outcomes including weight gain and CD4 count increase.
Baseline values were the last measurements (within
159 days) prior to ART initiation, and on-treatment values
were the last measurement between 180 and 365 days after
ART initiation. This window was selected to maximize the
number of participants with on-treatment assessment.
Differences between baseline and on-treatment weight and
CD4 count were calculated, then divided by the time in
years after ART initiation, to account for differences in
each participant’s assessment time-point. Linear regression
was then performed to identify associations between
patient group and weight gain or CD4 increase. Potential
confounders identified a priori (i.e., age category, prior
therapy, second-line regimen) and those with a
p value \ 0.10 in bivariable analysis were selected for
inclusion in multivariable models.
A two-sided p value \ 0.05 was significant. Stata/IC
version 12.1 (StataCorp LP, College Station, Texas) was
used for all analyses.
Results
Cohort at Baseline
Between July 20, 2005 and March 1, 2011, 250 HIV-1-
seropositive participants enrolled, including 127 women
and 123 men, of whom 108 were classified as MSM and 15
as heterosexual for this analysis. Three men reported only
female partners at enrollment, but reported sex with male
partners at least once during follow-up, and so were clas-
sified as MSM. Table 1 compares demographic and health
characteristics of participants at enrollment. There were
significant differences across groups in marital status,
having dependents, income, and transactional sex work.
There were no differences in CD4 count, WHO stage,
nutritional status, illness, or prior TB. MSM and hetero-
sexual men were less likely than women to have disclosed
their HIV status, used co-trimoxazole prophylaxis, had
ART counseling, or ever taken ART at baseline, although
differences in co-trimoxazole use were of borderline
significance.
Loss to Follow-Up
After the initial visit, eight MSM and eight women did not
return, and one MSM withdrew; these 17 participants
therefore had no follow-up visits. Among 233 participants
with at least one follow-up visit, 57 MSM (57.6 %), 10
heterosexual men (66.7 %), and 81 women (68.1 %)
remained in follow-up on March 1, 2011. Two MSM
(2.0 %) and three women (2.5 %) had died; 37 MSM
(37.4 %), 5 heterosexual men (33.3 %), and 35 women
(29.4 %) were lost to follow-up; and 3 MSM (3.0 %) had
withdrawn from the clinic. In total, 77 participants were
lost to follow-up from the cohort over 646.3 person-years,
for a rate of 11.9 patients lost (95 % confidence inter-
val [CI], 9.5–14.9) per 100 person-years of observation.
Figure 1 presents the Kaplan–Meier failure curves for loss
to follow-up in each group. Although MSM had the highest
rate of loss to follow-up, this difference was not significant
(14.5 per 100 person-years for MSM, 9.2 per 100 person-
years for heterosexual men, and 10.4 per 100 person-years
for women; v2 = 1.60, p = 0.45 by log-rank test). Table 2
presents a multivariable analysis of factors associated with
loss to follow-up. Younger participants were more likely
(adjusted hazard ratio [aHR] 1.90, 95 % CI 1.00–3.62 if
aged 18–24 years relative to C35 years), and participants
receiving ART through the research clinic were less likely
(aHR 0.42, 95 % CI 0.19–0.94) to be lost to follow-up.
ART Initiation
Sixty-eight participants, including 30 MSM, 8 heterosexual
men, and 30 women started ART at the research clinic.
Fig. 1 Kaplan–Meier curves for the probability of loss to follow-up
after cohort enrollment by patient group (female, MSM, or hetero-
sexual male)
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Table 2 Associations with loss to follow-up after enrollment, n = 233
Characteristic Baseline
N (%)
HR (95 % CI) p value aHR (95 % CI)a p value
Risk group
Female 119 (51.1) Reference Reference
MSM 99 (42.5) 1.33 (0.84–2.11) 0.23 1.33 (0.83–2.14) 0.24
Heterosexual males 15 (6.4) 0.97 (0.38–2.47) 0.94 1.12 (0.44–2.87) 0.82
Age groupb
18–24 years 49 (21.0) 2.24 (1.21–4.16) 0.01 1.90 (1.00–3.62) 0.05
25–34 years 133 (57.1) 0.83 (0.48–1.41) 0.49 0.72 (0.42–1.25) 0.24
35 and older 51 (21.9) Reference Reference
Marital status
Single 154 (66.1) Reference
Married 26 (11.2) 1.11 (0.58–2.14) 0.74
Widowed, separated, or divorced 53 (22.8) 0.92 (0.53–1.62) 0.78
Has dependents 127 (54.5) 0.79 (0.50–1.23) 0.30
Educational achievement
None or primary school only 141 (60.5) Reference
Secondary school 76 (32.6) 0.88 (0.54–1.43) 0.60
Higher education 16 (6.9) 0.75 (0.27–2.08) 0.58
Monthly earnings
C10,000 KSh 35 (15.0) Reference
5,000–9,999 KSh 60 (25.8) 1.61 (0.77–3.38) 0.21
2,000–5,000 KSh 84 (36.0) 0.99 (0.47–2.09) 0.99
\2,000 KSh 54 (23.2) 1.46 (0.69–3.10) 0.32
Transactional sexb 173 (74.2) 1.27 (0.81–1.99) 0.30
Alcohol useb 157 (67.4) 1.08 (0.69–1.69) 0.74
CD4 countb
\200 32 (13.7) Reference
200–350 60 (25.8) 0.74 (0.35–1.58) 0.44
[350 141 (60.5) 0.69 (0.35–1.37) 0.29
WHO stageb,c
I asymptomatic/lymphadenopathy 91 (39.2) Reference
II mild local manifestations 87 (37.5) 1.12 (0.62–2.01) 0.71
III systemic manifestations 52 (22.4) 1.09 (0.57–2.08) 0.80
IV AIDS-defining illness 2 (0.9) 0.78 (0.10–5.91) 0.81
Nutritional statusb
Adequate nutrition 185 (79.4) Reference
Mild to moderate malnutrition 46 (19.7) 1.27 (0.18–9.19) 0.81
Severe malnutrition 2 (0.9) 1.31 (0.70–2.43) 0.40
Too sick to work, past 3 monthsb,c 41 (17.6) 0.38 (0.09–1.57) 0.18
Taking TB treatment, past 3 monthsb,c 12 (5.2) 0.56 (0.08–4.05) 0.57
Disclosure of HIV statusc,d 101 (43.7) 1.12 (0.71–1.75) 0.63
ART useb
None 196 (84.1) Reference Reference
Research clinic 1 (0.4) 0.45 (0.20–0.99) 0.05 0.42 (0.19–0.94) 0.04
Outside clinic 36 (15.5) 0.66 (0.29–1.54) 0.34 0.68 (0.29–1.59) 0.37
aHR adjusted hazard ratio, HR hazard ratio
a Likelihood ratio v2 = 17.70, degrees of freedom = 6, p = 0.007
b Time-dependent covariate. Note that although only one participant started ART at the research clinic immediately upon enrollment, 25.5 % of included follow-up
visits were contributed by participants taking ART at the research clinic and 9.4 % by participants taking ART at an outside clinic
c Data were missing for WHO stage (2 visits), being too sick to work (225 visits), TB treatment (221 visits), and disclosure (21 visits). The total of included follow-
up visits was 2,667
d Disclosure was defined as informing anyone other than the counselor or medical staff (e.g., family, partner, friend, other) about one’s HIV infection
1260 AIDS Behav (2013) 17:1255–1265
123
These participants did not differ with respect to nutritional
status, CD4 count, WHO stage, co-trimoxazole use, TB
treatment, prior ART use, or disclosure of status at base-
line. Two MSM were lost to follow-up immediately after
starting ART, and eight participants (four women, three
MSM, and one heterosexual male) initiated ART the month
before the study closed and had no on-treatment follow-up.
The 58 participants included for analysis of ART out-
comes were followed for 140.6 person-years, with a med-
ian of 856 days per person on treatment (interquartile range
[IQR], 583–1,276 days). There was no difference in fol-
low-up time on ART by patient group (KW v2 = 0.30,
p = 0.86). After ART initiation, one MSM (4.0 %) died of
sepsis at 10 months and one woman (3.8 %) died of
tuberculosis at 3 months. The mortality rate was 1.4 (95 %
CI, 0.4–5.7) per 100 person-years, with no difference
between groups (v2 = 0.29, p = 0.87 by log-rank test).
Three MSM, two heterosexual men, and two women had
been on tuberculosis treatment at ART initiation, and three
MSM were diagnosed with active tuberculosis 130, 377,
and 632 days after ART initiation. Four MSM (16.0 %)
and four women (15.4 %) were lost to follow-up, and eight
MSM (32.0 %) and one heterosexual man (14.3 %) trans-
ferred care. The overall rate of loss to follow-up was 5.7
(95 % CI, 2.8–11.4) per 100 person-years, with no differ-
ence between groups (v2 = 1.27, p = 0.53 by log-rank
test).
Median adherence did not differ across groups, at
98.8 % (IQR, 90.1–99.8 %) for MSM, 99.5 % (IQR,
91.9–100 %) for heterosexual men, and 99.2 % (IQR,
96.4–100 %) for women (KW v2 = 3.17, p = 0.20). There
was no significant difference in ever having a late refill
(72.0 % for MSM, 57.1 % for heterosexual men, 50.0 %
for women; FE p = 0.29). However, 40 % of MSM had
adherence \95 %, versus 28.6 % of heterosexual men and
11.5 % of women (FE p = 0.047).
ART Outcomes
Outcomes after 6–12 months of ART were assessed in 47
(81 %) of 58 participants included in the above analysis.
The 11 participants in whom outcomes could not be
assessed either died (n = 2), were lost to follow-up
(n = 4), or transferred care (n = 2) before the outcome
window or had taken ART for \6 months (n = 3). On-
treatment weight was assessed a median of 310 days after
ART initiation (range, 219–364 days) and on-treatment
CD4 count was assessed a median of 314 days after ART
initiation (range, 219–364 days). Assessment timing did
not differ by group (KW v2 = 0.37, p = 0.83 for weight
gain; KW v2 = 0.56, p = 0.75 for CD4 increase).
At assessment, fewer men than women had gained
weight (36.4 % of MSM and 50.0 % of heterosexual men
vs. 73.7 % of women, FE p = 0.06) or had a CD4 count
increase (72.7 % of MSM and 16.7 % of heterosexual men
vs. 79.0 % of women, FE p = 0.01). Table 3 presents
linear regression analyses of weight gain per year and CD4
increase per year as clinical outcomes after ART initiation.
Mean weight gain was -0.2 kg/year for MSM (standard
deviation [SD], 3.4 kg/year) and 4.1 kg/year for hetero-
sexual men (SD, 7.5 kg/year) vs. 3.1 kg/year for women
(SD, 4.9 kg/year). The mean CD4 count increase was 56.9
cells/year for MSM (SD, 130.2 cells/year) and -4.5 cells/
year for heterosexual men (SD, 56.5) vs. 158.0 cells/year
for women (SD, 196.9 cells/year). Lower weight gain
among MSM relative to women remained significant after
adjustment for potential confounders, including tubercu-
losis. Although CD4 count increases were lower in MSM
and heterosexual men relative to women in unadjusted
analysis, this difference was not significant in adjusted
modeling.
Discussion
In this small pilot study of HIV care provision to most-at-
risk populations in coastal Kenya, both heterosexual men
and MSM were less likely than women to report having
disclosed their HIV status, had ART counseling, or ever
taken ART at enrollment, indicating a low level of
engagement with health services in the community. MSM
were retained at similar rates to those of heterosexual male
and female participants, with C80 % retention at
12 months in all three groups. Participants receiving ART
through the research clinic were more likely to be retained
in care than those not receiving ART, and younger par-
ticipants were more likely to be lost to follow-up, regard-
less of patient group. Of note, these barriers experienced by
our clinic population (i.e., pre-ART status, younger age)
also pertain to other populations of HIV-1-infected adults
[22–24].
While men and women had similar health status at ART
initiation, MSM had the lowest overall adherence and poor
weight gain during treatment. Although three MSM
developed tuberculosis after ART initiation, weight gain
was not associated with tuberculosis. Both MSM and het-
erosexual men had suboptimal CD4 counts compared to
women, but these differences were not significant in
adjusted analysis. These findings support our general
impression that among adults reporting high-risk sexual
practices, MSM may face greater barriers to ART adher-
ence that could reduce treatment response. Because our
population of heterosexual men was very small, it is dif-
ficult to draw conclusions from their data.
The role of gender in antiretroviral adherence and
response to therapy has varied in different settings and
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populations. In developed countries, a systematic review
found little difference in treatment outcome by gender,
although women were thought to have worse adherence
and more frequent treatment interruptions than men, pos-
sibly due to higher rates of adverse reactions [25]. In
contrast, several studies conducted in Africa have reported
that men have worse clinical outcomes, lower adherence
rates, and lower retention in care than women [26–32]. In
this respect, our findings are in accordance with an
emerging body of evidence. Several reasons for sub-opti-
mal outcomes among African men have been proposed,
including biologic factors such as differences in drug
metabolism, toxicities, and opportunistic infection rates, as
well as later presentation to care [28–30, 32]. However,
these factors have not fully explained poor clinical out-
comes among men. One study noted that men who pre-
sented for care with their spouses had better outcomes,
suggesting that married men may face fewer barriers to
care [32]. Additional study of sociobehavioral factors has
been proposed, including a review of sociocultural and
policy differences between programs in resource-limited
settings and resource-rich settings [28–30].
A key difference in sociocultural milieu and policy
between many resource-limited and resource-rich settings
is service delivery to MSM. Adult same-sex behavior is
criminalized and socially unacceptable in many African
countries, including Kenya [2]. Stigma, discrimination, and
social isolation may seriously undermine the ability of
criminalized groups such as MSM to engage in and adhere
to care [6, 7]. Evidence suggests that MSM suffer from
poor access to HIV-1 testing and prevention services, fear
of health-care seeking, denial of care, and even blackmail
[5, 6]. These problems may be exacerbated among MSM
who rely on sex work for their living, given the increased
stigma this entails. It is noteworthy that we identified poor
ART outcomes despite a research program specifically
oriented towards engaging MSM in care, with counselors
trained in male sexual health. Because the vast majority of
ART programs in Africa do not specifically identify MSM
among their male patients nor provide services targeted to
these men’s needs, it is unknown to what degree poor
outcomes among African male patients in general may be
related to MSM identity.
With the recent success of the HPTN 052 trial, in which
ART reduced HIV-1 transmission within discordant cou-
ples by an estimated 96 % [13], there is growing interest in
prevention in positives and ‘‘find, test, link, and retain in
care’’ models [33–35]. The success of such approaches will
depend critically on whether HIV-1-infected persons can
engage in care, adhere to therapy, and remain in care [8]. It
is unclear why the MSM in our study had worse overall
adherence and poor weight gain on treatment than female
cohort participants. Both groups were similar with respect
to age, education, and income levels, and both frequently
reported transactional sex work and alcohol use. While
several clinic attendees have complained of poor access to
adequate food and housing, we did not collect data on food
intake or ability to prepare food. Qualitative research
regarding African men’s experiences using ART has
identified concerns about lack of control and the ability of
health care staff to maintain confidentiality [36], but has
not addressed other factors that may influence clinical
outcomes. Key research priorities recently identified for
MSM in Africa include increasing adherence to biomedical
interventions and promoting structural interventions to
improve access to care [37].
To our knowledge, this is the first study to specifically
report on ART outcomes among African MSM, who have
only recently become a focus for HIV prevention and
treatment programs. However, this study has several
important limitations. First, the sample size and follow-up
time were limited in this small pilot program. In particular,
there were very few heterosexual men in our cohort, so
comparisons with this group lack statistical power. Second,
the clinic focused on recruitment of men and women
reporting high-risk sexual behavior, including anal sex and
transactional sex work. As such, these results may not be
generalizable to other settings. Third, stigma due to the
criminalization of adult same-sex behavior may have led to
bias in the reporting of sexual risk behavior and the mis-
classification of MSM as heterosexual men. Fourth, our
ability to track patients after missed visits was restricted to
patients taking ART due to limited resources, and we were
unable to determine outcomes for participants who were
lost to follow-up; in general, we note that mortality was
uncommon within the retained cohort, loss to follow-up
was not associated with CD4 count or WHO stage, and
HIV care was available at several non-research facilities in
the clinic catchment area. Fifth, weight and CD4 count
were not all assessed at the same time-point, and plasma
viral load was unavailable. Despite these limitations, we
feel it is important to share our experience providing care
to this highly stigmatized group.
Conclusion
We have found that in a research cohort targeting most
at-risk populations in Kenya, participating men, including
MSM, were less likely than women to have disclosed their
HIV status, had ART counseling, or ever taken ART in the
community prior to enrollment. Although men and women
had similar health status at ART initiation, MSM had lower
adherence and a less robust on-treatment weight gain when
compared to women attending the same clinic. Although
this study could not definitively address differences in
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clinical outcomes between MSM and other patients, our
results suggest that further research into healthcare dis-
parities affecting African MSM is warranted. Effective
interventions to address barriers to access, adherence, and
retention among African men are needed, with specific
attention to monitoring outcomes among MSM.
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